HealthTech startup ecosystem
European healthtech startups are transforming care delivery, diagnostics, and drug discovery. Strong public health systems create natural testing grounds, while regulatory clarity through CE marking and the MDR framework gives European companies a path to scale. We track 207 organisations in this sector across 6+ countries.
Showing 1–20 of 207 HealthTech
Countries in this sector
Sectors alongside this one
HealthTech results
-
.lumen
Deep-tech firm building AI-powered smart glasses that replicate guide-dog function for the visually impaired, using pedestrian autonomous-driving perception and haptic head-steering. Tested with 300+ blind users across ~30 countries.
-
50 Partners
Founded 2012 by 50 entrepreneurs. Accelerator offering hands-on mentorship and seed investment for tech, impact, and healthtech ventures; the mentor network includes founders behind BlaBlaCar, Le Bon Coin, and Showroomprivé. Support: equity investment, mentorship, Paris workspace. Scope: National.
-
500 Istanbul
500 Istanbul is an Istanbul-based early-stage venture capital fund established in 2016 by Enis Hulli and Rina Onur Şirinoğlu in partnership with 500 Global, operating as a distinct fund entity focused on Turkey and Emerging Europe. The fund raised a €30M Fund II and later evolved into 500 Emerging Europe, targeting a €70M raise for the broader CEE and Baltics region. Its portfolio of 37+ companies includes three unicorns — Insider, BillionToOne, and Carbon Health — with portfolio companies collectively generating over $600M in annual revenue and attracting $1.1B in follow-on funding. The fund backs pre-seed to seed-stage startups with typical cheques from €200K to €3M.
-
6th Digital Health Conference 2026
A focused digital-health conference bringing pharma leaders, DTx specialists, regulators, and investors together around AI, real-world data, and patient-centric innovation. For digital-health founders it offers targeted access to pharma partners and regulatory expertise.
-
ACT Venture Capital
ACT Venture Capital is Ireland's most established and most active venture firm, founded in 1994 and headquartered in Dublin. Over three decades it has backed more than 140 Irish and European technology companies, raising over €600M across six funds — including its largest, a €140M fund closed in 2022 — and generating dozens of exits with a combined enterprise value of around €4.6bn. Its limited partners include the European Investment Fund, Enterprise Ireland, the Ireland Strategic Investment Fund and AIB, several of whom have backed the firm for more than twenty years. Led by Managing Partner John Flynn alongside General Partners Debbie Rennick and John O'Sullivan, ACT invests from seed to expansion stage with cheques up to €10M across software, AI, deep tech, health tech, energy and fintech in Ireland and the UK. Landmark outcomes include the $400M sale of UWB semiconductor company Decawave to Qorvo (2020), the acquisition of digital-mental-health platform SilverCloud Health by Amwell (2021), and SoftBank's €473M investment into connected-vehicle company Cubic Telecom at a €900M+ valuation (2024). Recent active deals include AI pathology company Deciphex and energy-optimisation platform GridBeyond.
-
Ada Ventures
Ada Ventures is a London-based pre-seed and seed fund founded in 2019 by Check (Francesca) Warner MBE and Matt Bradley, focused on backing diverse founders building breakthrough technology across climate equity, economic empowerment, and healthy ageing. The firm closed its first fund at $50 million and raised a second fund of £63 million in March 2024, bringing total assets under management to over £100 million. Ada distinguishes itself as Europe's first VC fund explicitly designed to address underrepresentation in the startup ecosystem, investing £250K–£1M per company and running a scout and angel programme to surface talent overlooked by traditional networks.
-
Advanced Therapies Congress 2026
Europe's largest cell and gene therapy event. Price: about GBP 2000; startups often access subsidized exhibition pods. Strong for biotech founders and manufacturing partners.
-
Advanced Therapies Congress 2027
The Advanced Therapies Congress runs 9-10 March 2027 at ExCeL London, billed as Europe's largest commercial cell and gene therapy conference and exhibition. It brings together around 3,300 global executives, 300 speakers and 75 startups spanning ATMP companies, pharma, biotech, researchers, clinicians and regulators.
-
Agesync
Agesync (Agesync GmbH), established in 2024 and based in Berlin (with a presence in New York), is a physician-led longevity platform that combines at-home blood diagnostics measuring 40-60+ biomarkers with a network of licensed EU doctors who review results and prescribe personalized hormonal therapy, nutrition, training, and supplement protocols. Its dashboard tracks biomarker trends, protocol adherence, and wearable data such as HRV and sleep over quarterly retesting cycles, and its labs are ISO 15189-certified partners in the EU and US.
-
AI Summit Adria 2026
Invite-style AI & Data summit at Hotel Histria for 200 senior leaders across banking, telecom, healthcare, retail and public sector, with 50+ speakers focused on business value of enterprise AI.
-
AI Summit Budapest 2026
Central Europe's largest AI conference, hosted at Magyar Zene Háza and Néprajzi Múzeum in Városliget. 12 sections and 100+ speakers cover AI across business, healthcare, employment, creative, and ethics.
-
Alan
Alan is a Paris-based health insurance and digital health platform founded in 2016 by Jean-Charles Samuelian-Werve (CEO) and Charles Gorintin (CTO) — the only new independent health insurer licensed in France since 1986. It combines group and individual health insurance with a mobile super-app offering reimbursements, telemedicine, mental-health support (Alan Clinic) and Mo, an AI health assistant delivering doctor-reviewed answers. By early 2026 Alan served over one million members across France, Belgium, Spain and Canada, with €785M ARR in 2025 (up 53%) and operational profitability in France. Alan has raised roughly €754M across eight rounds. It reached unicorn status in 2021 with a €185M Series D led by Coatue, and in March 2026 a €100M Series G led by Index Ventures — a backer since its Series A — valued the company at €5bn. Other investors include Temasek, Teachers' Venture Growth, Coatue, Lakestar, Partech, Belfius and DST Global.
-
ALBUPAD
Developed a proprietary biomaterial made from albumin — fully biocompatible and biodegradable — engineered for next-generation drug delivery and tissue engineering, with natural tumour tropism and built-in imaging visibility. Founded 2023.
-
Alexandre Lebrun
Co-founder and CEO of Nabla, the clinical-AI assistant for clinicians. A repeat AI founder, he previously built VirtuOz and Wit.ai (acquired by Facebook) and led conversational-AI research at Meta.
-
Algalíf
Algalíf is an Icelandic biotechnology company founded in 2012 that produces high-grade natural astaxanthin from microalgae using 100% renewable geothermal energy in a fully enclosed indoor photobioreactor system. The company is certified carbon-negative, binding 75 tonnes of CO2 annually, and holds over $50M in cumulative investment. In 2025 Algalíf launched Astalíf 15, the world's first 15% natural astaxanthin oleoresin, and broke ground on the world's largest natural astaxanthin facility (12,500 m²). The board initiated IPO preparations for 2025 and appointed new leadership following the departure of long-serving CEO Orri Björnsson.
-
Alithea Bio
Accelerates cancer immunotherapy development with its HLA-Compass platform, a large quantitative database of HLA peptide presentation. AI-driven analytics predict off-target toxicity and support target discovery for safer, more precise therapies.
-
Altenpflege 2026
Germany's leading trade fair for nursing and elderly care services, attracting care providers, hospital managers, and technology vendors. Features exhibitions on care-tech, assistive robotics, and patient monitoring innovations. Day tickets cost about EUR 30. Particularly relevant for HealthTech and robotics startups targeting the aging population sector.
-
Altenpflege 2027
Altenpflege's next edition is confirmed for 20-21 April 2027 in Essen. Germany's leading trade fair for nursing and elderly care services attracts care providers, hospital managers, and technology vendors showcasing care-tech, assistive robotics, and patient monitoring innovations.
-
Amber Therapeutics
Amber Therapeutics is an Oxford-based bioelectronics medtech company developing next-generation implantable neuromodulation devices for pelvic and nervous system disorders such as overactive bladder. Spun out from the University of Oxford, the company combines advanced microelectronics with closed-loop stimulation algorithms that adapt treatment in real time based on patient physiology. Amber has raised funding from deep-tech and life-science investors to advance its platform through clinical development. The company represents a growing wave of UK-based bioelectronic medicine startups tackling chronic conditions with precision device therapies.
-
Aptamedica
Aptamedica is a Warsaw-based medtech startup developing a real-time, point-of-care therapeutic drug monitoring platform for intensive and critical care. Its core product, AptaSense, is a bedside analyzer that uses single-use, aptamer-based (DNA biosensor) test strips to measure blood concentrations of antibiotics such as vancomycin, gentamicin and amikacin, plus the sepsis biomarker procalcitonin, returning results in roughly one minute from a venous sample — removing the need to send samples to a central lab and enabling immediate, precise dosing. The platform extends beyond the handheld analyzer: AptaFlow integrates into haemodialysis circuits for continuous real-time drug monitoring, while AptaSoft is an AI-assisted dosing tool aimed at neonatal care. New analytes such as troponin and digoxin are in the development pipeline and can be added via software. Founded by Maciej Łach, Mateusz Fil and Kamil Pawełkiewicz, the company is at prototype stage and has taken part in Polish innovation programmes including Warsaw Booster and the Mother and Child Startup Challenge; no external funding round has been publicly disclosed to date.
